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COMMENTARY
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Giovanni Passalacqua6, Giorgio Walter Canonica6 and Italian Allergic Respiratory Diseases Task Force
Abstract 
In a historical period in which sustainability of the National Health Service is mandatory because of the international 
economical situation, the limited available resources at national level and the tendency of passing from a “popula‑
tion medicine” model towards the concept of “individualized medicine”, the debate on appropriateness of medical 
and surgical procedures is of central importance. The choosing wisely campaign, started in United States in 2012 and 
then spread all over the world, tries to summarize which are the most inappropriate procedures for each medical and 
surgical speciality; as far as allergic respiratory diseases, the most relevant Italian societies and the American Academy 
defined the allergological procedures with the highest probability of inappropriateness. In Italy, a recent decree of 
the Ministry of Health defined a list of more than 200 procedures that will be considered as inappropriate in certain 
conditions; many of these procedures concern allergology, including allergic respiratory diseases. In this commen‑
tary we discuss the above mentioned decree and the concept of appropriateness in the field of allergic respiratory 
diseases, trying to figure out some practical considerations based on the current health resources available in the field 
of allergology in Italy.
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Background
Appropriateness policies have the main goal to both 
contain health care spending and efficiently redistribute 
resources. In fact, the inappropriateness may be in excess 
(“overuse”) or in defect (“underuse”): the reduction of the 
first one recovers lost resources, and the implementa-
tion of the second one requires investments [1]. There-
fore, any strategy to reduce the inappropriateness must 
be guided by the principle of “disinvestment and reallo-
cation.” Today, a medical prescription can not take into 
account only the individuality of each patient (“individu-
alized medicine”), but also the unacceptable variability in 
the requirements (“population medicine”) and the fact 
that every doctor is required to contribute, as manager of 
public resources, to sustainability of the National Health 
Service. Until a few decades ago, the work of the clini-
cians did not pose the question of the appropriateness 
so urgently as today: the aim of the physician at the bed-
side appeared unique, the tools to achieve it were few and 
the simple medical evaluation was more than enough. 
Current clinical practice instead it is a complex activity 
that involves different purposes, therefore taking into 
account many heterogeneous elements. Appropriate-
ness is often treated as a single concept. However, there 
are two distinct types of appropriateness: “professional” 
appropriateness, closely linked to the cultural level of the 
health care and decision-making, and appropriateness of 
the setting in which care is provided [2]. It is therefore 
clear that these two distinct levels of appropriateness 
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must necessarily be synergistic and not discordant. Also, 
appropriateness cannot be separated from other essential 
concepts: efficacy, effectiveness and cost-effectiveness. 
When quality of healthcare is the matter of Healthcare, 
as universally agreed, quality must be effective, efficient, 
safe, humanized and consider the economic resources 
[3]. Furthermore, it is equally essential that the appropri-
ateness is applied within the concept of evidence-based 
medicine (EBM) [4]. Finally, appropriateness should 
always be linked to avoidance of over diagnosis malprac-
tice [5]. A shift in dynamics of diagnostic medicine to 
behaviors of appropriateness also well correlates with the 
new cultural movements of “choosing wisely” and “slow 
medicine”. choosing wisely is an initiative launched by 
the ABIM Foundation and then spread all over the world. 
choosing wisely aims to promote the interaction between 
clinicians and patients in order to support patients in 
choosing care that is supported by evidence, not dupli-
cative of other tests or procedures already received, free 
from harm, and truly necessary [6–9].
Choosing wisely recommendations meant to identify 
which are appropriate and necessary procedures or treat-
ments. As each patient situation is unique, providers and 
patients should use the recommendations as guidelines 
to determine an appropriate treatment plan together. In 
other words, a diagnostic or therapeutic procedure can 
be considered appropriate when it is delivered according 
to clinical indications with proven efficacy, at the right 
time, in accordance with appropriate mode. In Italy, the 
appropriateness of healthcare is increasingly gaining the 
interest health care providers and policy-makers. In fact, 
in Italy, a major topic of the current health care debate is 
that a substantial proportion of the health care delivered 
is inappropriate. Recently, the Italian Ministry of Health 
has presented a decree, known as “Appropriateness 
Decree”. This decree has been published in the “Gazzetta 
Ufficiale” of January 20, 2016, and it contains a list of 
more than 203 diagnostic tests with the criteria of appro-
priateness and prescriptive constraints. The “Gazzetta 
Ufficiale” is a document containing the laws passed by 
the government.This action arised a widespread medi-
atic debate, as the unusual pairing of the prescription 
appropriateness (“cultural and professional”) and penalty 
mechanisms (“contractual interest and trade union”) have 
been considered to be insufficiently shared with medi-
cal doctors. Since respiratory allergies (oculorhinitis and 
bronchial asthma) have an important epidemiological 
and social health impact, it becomes important to estab-
lish a “virtuous” diagnostic flow chart that must be in line 
with the innovative concepts of appropriateness, and the 
new findings on diagnostic procedures. Within the phy-
sicians (allergists, pulmonologists, pediatricians, general 
practitioners, etc.) that interface with patients suffering 
from respiratory allergies, it also becomes important to 
establish “who does what” and make the harmonious 
interplay between the various health care providers. Pur-
pose of this article is to make a contribution to improve 
these dynamics. The fundamental objective in approach-
ing allergic respiratory diseases is that each patient 
receives the procedures with the best possible outcome 
and satisfaction based on knowledge available, the least 
risk of damage following treatment and the lowest con-
sumption of resources (Fig. 1).
Slow medicine, choosing wisely and allergic 
respiratory diseases
In the latest few years, the concept of a “slow medicine” 
approach to clinical problems gained a worldwide inter-
est, being also endorsed by the former British Medical 
Journal (BMJ) editor in chief, professor Richard Smith, 
who wrote that “slow medicine —like slow food and slow 
lovemaking—is the best kind of medicine for the twenty 
first century” [10].
“Slow medicine”, as a concept, has been coined by 
Alberto Dolara, an Italian cardiologist that in 2002 
invited his colleagues to give the deserved value to the 
time spent in improving the patient-doctor relationship, 
implementing a more “human and thoughtful medicine” 
[11]. However, the underlying concepts were somehow 
anticipated from some philosophers such as Ivan Illich 
that, with his “medical nemesis” published in 1974, 
argued that the medicalization in recent decades of so 
many of life’s vicissitudes—including birth and death—
and the so called “hubris of medicine” frequently caused 
more harm than good and rendered many people in 
effect lifelong patients [12].
Into the context of the “slow medicine” international 
movement, it recently emerged the need to approach 
one important clinical problem that every physician 
faces in everyday clinical practice: the mis-use and 
over-use of medical resources (including useless exams, 
Fig. 1 Fundamental components and objectives to improve the 
appropriateness and the quality of health care
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surgical interventions, medical treatments, screening 
procedures…) which is well known to lead to increased 
healthcare costs (without a proportional patients’ benefit) 
[13] and possible harm to the patients themselves [14]. 
The immediate consequence of this, was the emerging 
of the so-called “choosing wisely” campaign (firstly 2012 
in USA and then spread in several other countries) [15, 
16] with the main goal of identifying the most inappro-
priate medical procedures for each specialty (those medi-
cal procedures that should be deeply discussed with the 
doctor because can be useless in the diagnostic work-up 
and even potentially harmful), to protect patients’ inter-
ests through a partnership between health professionals 
and patients and users [17]. In Italy, this campaign took 
the name of “Doing more does not mean doing better” 
[18, 19] and it has been coordinated by slow medicine 
Italy [20] which invited the most relevant Italian scien-
tific societies to list of the five medical procedures with 
the highest probability of inappropriateness for each spe-
cialty (the Italian Society of Allergy, Asthma and Clini-
cal Immunology, SIAAIC as far as the Italian Society of 
Pediatric Allergy and Immunology, SIAIP adhered to the 
projects producing their lists of inappropriate procedures 
[21, 22].
Focusing on respiratory allergic diseases, SIAAIC iden-
tified one important inappropriate procedure that was 
stated as: “Do not diagnose asthma without having per-
formed lung function tests (including bronchodilator test 
and/or bronchial challenge)” [21]. A similar recommen-
dation was made by the American Academy of Allergy, 
Asthma and Immunology (AAAAI) into the context of 
the American choosing wisely campaign (“Don’t diag-
nose or manage asthma without spirometry”) [23].
Into a recent description of “choosing wisely” cam-
paign promoted by SIAAIC [21], the authors explained 
that relying only upon asthma-like symptoms (i.e., dysp-
nea, chest tightness, cough, wheezing) is not sufficient 
to make a correct diagnosis of asthma, as these symp-
toms may be due to other causes (i.e., chronic obstruc-
tive pulmonary disease (COPD), congestive heart failure, 
gastroesophageal reflux disease, hyperventilation syn-
drome, etc. [24–27]. Putting a diagnosis of asthma based 
only on symptoms can be harmful for patients, as they 
may be receive a wrong treatment for their complaints. 
This aspect is even more important when patients suffer 
from relevant comorbidities, as it happens in the elderly 
[28]. International asthma guidelines stress the need of 
performing lung function assessment to identify bron-
chial hyperreactivity and/or reversibility of bronchial 
obstruction [29]. Patients with asthma-like symptoms 
and normal spirometry should underwent a non-spe-
cific bronchial challenge (i.e.: with methacholine) while 
those with an obstructive spirometric pattern should be 
evaluated for reversibility with a bronchodilating test 
(i.e., with salbutamol). Beyond the increased costs of 
care, the consequences of misdiagnosing asthma include 
delaying a correct diagnosis and treatment [26]. The 
same Authors suggested also not to perform serologi-
cal allergy tests (i.e., total IgE, specific IgE, component-
resolved diagnosis) as first-line tests or as “screening” of 
respiratory allergy [21]. This is justified by the fact that 
cutaneous allergometric tests give faster results, are less 
invasive and cheaper than serological tests. Moreover, 
there is a moderate evidence that skin tests have at least 
the same diagnostic accuracy of serological tests [30, 31]. 
Exceptions to this recommendation have been identified 
in  situations in which cutaneous tests are not feasible 
(i.e., hypo- or hyper-reactive cutaneous states), or when 
an accurate skin prick test extract is not available [32], or 
if the clinical history suggests an unusually greater risk of 
anaphylaxis from skin testing [33] (this latest eventuality 
is very rare in the context of respiratory allergic diseases 
[34]. As far as total IgE assessment, SIAAIC recommen-
dation is that it is of limited clinical utility in most cases, 
as it is aspecific and not indicative of allergic sensitiza-
tion: allergic patients may have both normal or elevated 
total IgE levels, and patients with high total IgE levels 
are not necessarily atopic [32–35]. Measuring total IgE 
is otherwise indicated for the diagnosis of allergic bron-
chopulmonary aspergillosis, hyper IgE syndrome, as 
well as inclusion criterion for the correct prescription of 
anti-IgE therapy in severe allergic asthma [21]. Moreover, 
SIAAIC experts recommend that all serum allergologi-
cal tests should be interpreted by specialists/experts in 
allergy and clinical immunology, since an incorrect inter-
pretation can lead to inappropriate/useless therapeuti-
cal approaches, which may be harmful for the patient’s 
health [21]. Concerning the pediatric aspect (in addition 
to diagnostic procedures that are similar to adults) SIAIP 
identified one relevant inappropriate procedure in res-
piratory allergy work-up: “Do not give mucolytic agents 
to asthmatic children” [22]. In asthmatic children, in fact, 
airway inflammation, mucosal edema and mucus hyper-
secretion worsen bronchial obstruction by the formation 
of mucous plugs. Studies on mucolytics taken during 
asthma exacerbations or as add-on treatment of chronic 
therapy of asthma showed that these drugs are not able 
to improve asthma outcomes but they can even induce 
harmful adverse events [36–38].
Appropriateness, allergists, allergy setting, 
diagnostic procedures, and allergic respiratory 
diseases
The incidence and prevalence of bronchial asthma and 
allergic rhinitis are increasing worldwide. Allergic rhinitis 
currently affects between 10 and 30 % of the population. 
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Allergic rhinitis is a risk factor for asthma and its comor-
bidities of allergic rhinitis include: sinusitis, nasal poly-
posis, conjunctivitis, otitis media with effusion, upper 
respiratory infections, mouth breathing, and sleep dis-
orders. The prevalence of asthma in different countries 
varies widely, but the disparity is narrowing due to ris-
ing prevalence in low and middle income countries as 
they are adopting a more westernized lifestyle. In gen-
eral, patients with asthma are inadequately managed, 
and asthma and rhinitis are both under-recognized [39]. 
In addition, there is a large variation among countries in 
the delivery of care to those suffering from asthma and 
allergy [40]. What is common among countries, however, 
is that the majority of patients who seek medical advice 
for allergy and asthma are seen initially in primary care 
(or receive advices from pharmacists), because there is an 
inadequate number of allergists to meet the needs of so 
many patients [41]. As rightly stated in the World Allergy 
Organization (WAO) White Book [42]: “the allergist is an 
expert in tailoring therapy to the individual patient and 
adjusting treatment dosages in more severe or complex 
cases. The main defining characteristics of allergists are 
their appreciation of the importance of external triggers 
in causing diverse diseases; their expertise in both the 
diagnosis and treatments of multiple system disorders, 
including the use of allergen avoidance and the selec-
tion of appropriate drug and/or immunological therapies; 
and their knowledge of allergen specific immunotherapy 
practices. Misinterpretation of the results of diagnostic 
tests by nonspecialists can lead to over-diagnosis and 
inappropriate management which can be harmful for 
the patient. It may lead to over-prescription of therapy 
and costly and unnecessary allergen avoidance meas-
ures, including exclusion diets that can lead to nutri-
tional deficiency and secondary morbidity. Conversely, 
the under-appreciation of the severity of asthma can 
lead to life-endangering under-treatment or the lack of 
potentially life-altering immunotherapy. The cost-effec-
tiveness of allergist consultation will be demonstrated 
by improved patient outcomes and experiences, together 
with a reduction in unnecessary expenditure by payer, 
society or patient/family”. Therefore, The WAO White 
Book defines the central role of the Allergist in the man-
agement of allergic diseases to ensure an adequate level 
of health care and “appropriateness”.
So, allergic respiratory diseases generate an increase in 
healthcare-related costs, including secondary costs such 
as absenteeism and presenteeism at work and at school, 
if not properly treated. One of the challenges ahead is 
reconciling the pressing demand of increasingly complex 
performances with the progressive decrease in the num-
ber of allergists. A possible solution can be achieved from 
the educational role that the allergists should assume 
with respect to other health professionals, who contrib-
ute to the management of allergic diseases. This would 
result in a different levels-based management probably 
able to increase the overall efficiency of the system.
In Italy, up to now, there are some critical aspects 
because Allergology, even though it is recognized as a 
“precision professional field”; indeed, the basic levels of 
care (LEA = Livelli Essenziali di Assistenza) as presently 
defined consider allergy and dermatology as a unique area.
In the recent decree, known as “Appropriateness 
Decree” of the Italian Ministry of Health, the allergologi-
cal visit is the first and most important moment before 
starting the diagnostic work-up. The Appropriateness 
Decree ratifies that most allergometric tests (i.e., skin 
prick tests, patch tests, and intracutaneous tests), and 
some therapeutic procedures, like allergen-specific 
immunotherapy (AIT), can be performed only after an 
allergological visit, that is requested after a preliminary 
evaluation by a general Practitioner or a General Pedia-
trician. Furthermore, some procedures can be requested 
only by an allergy specialist: in  vivo tests for drugs and 
hymenoptera, and administration of immunotherapy for 
hymenoptera venom (VIT).
Finally, some in  vitro tests, as specific IgE dosage, are 
second level tools that must be performed only after 
in vivo tests or if skin prick test is not conclusive or not 
feasible. An in vitro test “as a screening” to evaluate res-
piratory allergy is not recommended. These recommen-
dations are in line with what suggested by SIAAIC in its 
“choosing wisely” document [21].
Anyway, the conditions to perform in  vitro tests 
depend on the appropriateness of the General Practi-
tioner request. It is also necessary to define the correct 
number and type of allergens to test. Usually the num-
ber of eight allergens is not exceeded, obviously chosen 
according to the botanic profile of each region. An exam-
ple of panel of largely present allergens could be: House 
Dust Mites (Dermatophagoides pteronissinus or farinae), 
grass (lolium, dactilis or festuca), birch, wall pellitory, 
alternaria, cat, dog, cypress or ragweed.
The component resolved diagnosis (CRD) is consid-
ered a third level tool. A molecular diagnosis allows to 
distinguish “false” from “true” sensitization in polisensi-
tized patients. The “WAO ARIA consensus document on 
molecular based allergy diagnostics”, emphasized its use 
in particular situations: in polisensitized patients it is used 
to evaluate if there is a true polisensitization to “genuine 
molecules” (Phl p 1, Phl p 5, Bet v 1, Amb a 1, Ole e 1, 
Cup a 1 Par j 2) or cross-reactivity to panallergens such as 
Profilin or Polcalcine, or to identify the trigger allergens in 
order to choose the correct immunotherapy [43].
A molecular diagnosis is essential to properly design the 
composition of allergen specific immunotherapy in patients 
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polisensitized to pollens. Several studies have demon-
strated that the use of CRD leads to a relevant change in the 
prescription of allergen immunotherapy [44].
Moreover, CRD may allows to identify the sensitiza-
tion patterns which are considered risk factor for severe 
asthma (i.e., some molds allergens: Alt a 1, Asp f 3, Asp 
f 4, or dog dander allergen: Can f 5) and the availability 
of these outcomes could anticipate the development of 
the disease and therefore identify those patients who will 
need more strict attention to prevent the onset of a more 
severe asthma.
More consistent with the interest of national health 
care services is the ability of CRD to identify food aller-
gens that represent a risk of anaphylaxis or of severe 
asthma attacks, (asthma associated with food allergy is 
usually severe or difficult to treat).
Another important aspect is the integrated management 
of severe asthma. Indeed, approximately 5  % of patients 
with asthma have a severe, treatment-refractory disease, 
with a high direct health-care costs (medication bur-
den) and high indirect costs (lost productivity). A recent 
study reported for the first time the efficacy of a system-
atic assessment at dedicated severe asthma centers in UK 
with a significant reduction in health-care use and oral 
steroid burden [45]. Mean oral steroid dose changed from 
about 15 mg to about 10 mg and fewer subjects required 
an oral steroid burst (91 vs 77 %). Hospital admission and 
primary care or emergency department visits were less, 
respectively from 48 to 38 % and from 88 to 76 %. It may 
be of interest for health care services to identify centers 
able to offer adequate respiratory and allergic diagnostic 
tools and complete care of the severe asthmatic patient, 
with a concrete control of the direct costs of therapy (i.e., 
biological agents or bronchial thermoplasty).
Conclusions
In Italy (but also in many other countries) there is a 
severe imbalance between the prevalence of allergic res-
piratory diseases and the number of hospital and com-
munity allergists. This could be improved through the 
following operational measures: increasing the number 
of specialists in allergy who each year graduate at the 
specialty schools; rebalancing the axis of hospital and 
community care, to develop in parallel both systems 
and the continuity of care; promoting a real integration 
between allergists and other physicians (i.e., pneumolo-
gists, ENTs, pediatricians, and general practitioners) in 
the care of the patients with allergic respiratory diseases; 
developing system solutions to ensure the taking over 
and the continuity of care of chronic illness and frailty 
(i.e., severe asthma or elderly patients); overcoming the 
fragmentation of the territorial organization; and main-
taining developing high quality hospital and territorial 
services through the establishment of clinical audit to 
verify the appropriateness of diagnostic and therapeutic 
procedures (Table 1).
Table 1 Proposal for  a real life distribution of  Italian 
health care resources for respiratory allergic diseases
TS territorial services, HS hospital setting, CPET cardiopulmonary exercise testing, 
VIT venom immunotherapy
a Resources to be present in clinical respiratory physiology unit
b Board certified centers










√ TS and HS I 
level
80–150
Skin prick test 
(inhalants, 
foods, latex)










√ TS and HS I 
level
80–150
















√ HS I level 150–300
Spirometry, 
DLCOa




√ HS I level 150–300
Mannitol 
challengea






√ HS I level 150–300
Exercise chal‑
lengea
√ HS I level 150–300




√ HS I–II level 300–600
Hymenopter‑
aVIT centerb




√ HS II level 600–1200
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To improve the appropriateness, in the field of respira-
tory allergy, a direct interaction between specialists and 
policy makers/institutions is mandatory, to better iden-
tify the medical needs and the patients’ needs and to 
properly re-allocate resources.
As a testification of the unmet needs ad of the claim for 
appropriateness, we convened this cross-sectional task 
force, which involved different specialists, different scien-
tific societies and a patients’ association. This document 
is therefore not intended as a guideline, or as a scientific 
statement, but rather as an approach to claim a more strict 
cooperation among all the involved health-care operators, 
including deciders and governmental authorities.
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